Histocell successfully completes the clinical safety phase of its cell therapy drug HC016 for the treatment of acute respiratory distress caused by COVID-19

by Histocell Regenerative Medicine

This is the Phase I clinical trial of the cell therapy drug HC016 developed by Histocell, which is being carried out at the Hospital de Cruces (Bilbao), in Spain. The objective of this trial is to off...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Memo Therapeutics increases Series C fin...

by Ysios Capital

Memo Therapeutics, a late-stage biotech company developing a best-in-c...

Photos Stream